170 related articles for article (PubMed ID: 37855027)
1. Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients.
Ninkovic S; Purton LE; Harrison SJ; Quach H
Haematologica; 2024 May; 109(5):1487-1500. PubMed ID: 37855027
[TBL] [Abstract][Full Text] [Related]
2. The Involvement of LAG-3
Kreiniz N; Eiza N; Tadmor T; Levy Yurkovski I; Matarasso Greenfeld S; Sabag A; Mubariki R; Suriu C; Votinov E; Toubi E; Vadasz Z
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203720
[TBL] [Abstract][Full Text] [Related]
3. Deep Learning Enables Spatial Mapping of the Mosaic Microenvironment of Myeloma Bone Marrow Trephine Biopsies.
Hagos YB; Lecat CSY; Patel D; Mikolajczak A; Castillo SP; Lyon EJ; Foster K; Tran TA; Lee LSH; Rodriguez-Justo M; Yong KL; Yuan Y
Cancer Res; 2024 Feb; 84(3):493-508. PubMed ID: 37963212
[TBL] [Abstract][Full Text] [Related]
4. The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets.
Steiner N; Müller U; Hajek R; Sevcikova S; Borjan B; Jöhrer K; Göbel G; Pircher A; Gunsilius E
PLoS One; 2018; 13(8):e0202045. PubMed ID: 30096165
[TBL] [Abstract][Full Text] [Related]
5. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
Front Immunol; 2020; 11():613007. PubMed ID: 33488620
[TBL] [Abstract][Full Text] [Related]
6. Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma.
Steiner N; Borjan B; Hajek R; Jöhrer K; Göbel G; Willenbacher W; Kern J; Gunsilius E; Untergasser G
Oncotarget; 2017 Aug; 8(34):56243-56254. PubMed ID: 28915587
[TBL] [Abstract][Full Text] [Related]
7. PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients.
Chen M; Zhu J; Yang X; Yao J; Liu Y; Liu Q
Eur J Med Res; 2022 Dec; 27(1):296. PubMed ID: 36529769
[TBL] [Abstract][Full Text] [Related]
8. Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice.
Hasanali ZS; Garfall AL; Burzenski L; Shultz LD; Tang Y; Kadu S; Sheppard NC; Liu W; Dopkin D; Vogl DT; Cohen AD; Waxman AJ; Susanibar-Adaniya SP; Carroll M; Stadtmauer EA; Allman D
JCI Insight; 2024 May; 9(10):. PubMed ID: 38713510
[TBL] [Abstract][Full Text] [Related]
9. [Expression and Significance of PD-1, PD-L1 and CTLA-4 in the Bone Marrow of Patients with Multiple Myeloma].
Li QZ; Peng J; Chen HM; Chen ZZ; Zhu ZW; Li LS; Hu GY; Yuan ZH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1803-1809. PubMed ID: 36476907
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD-1/PD-L1 pathway in multiple myeloma.
Zhang J; Liu Z; Cao P; Wang H; Liu H; Hua L; Xue H; Fu R
Cancer Med; 2022 Dec; 11(24):4838-4848. PubMed ID: 35593325
[TBL] [Abstract][Full Text] [Related]
11. [Expression of microRNA-221/222 in patients with monoclonal gammopathy of undetermined significance and multiple myeloma].
Yang S; Wang W; Jin H; Zhong Y; Xie X
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):371-378. PubMed ID: 27868410
[TBL] [Abstract][Full Text] [Related]
12. Mass Cytometry Discovers Two Discrete Subsets of CD39
Marsh-Wakefield F; Kruzins A; McGuire HM; Yang S; Bryant C; Fazekas de St Groth B; Nassif N; Byrne SN; Gibson J; Brown C; Larsen S; McCulloch D; Boyle R; Clark G; Joshua D; Ho PJ; Vuckovic S
Front Immunol; 2019; 10():1596. PubMed ID: 31428081
[TBL] [Abstract][Full Text] [Related]
13. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
[TBL] [Abstract][Full Text] [Related]
14. The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis.
Steiner N; Jöhrer K; Plewan S; Brunner-Véber A; Göbel G; Nachbaur D; Wolf D; Gunsilius E; Untergasser G
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825035
[TBL] [Abstract][Full Text] [Related]
15. PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma.
Tamura H; Ishibashi M; Sunakawa-Kii M; Inokuchi K
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290052
[TBL] [Abstract][Full Text] [Related]
16. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire.
Pérez-Andres M; Almeida J; Martin-Ayuso M; Moro MJ; Martin-Nuñez G; Galende J; Hernandez J; Mateo G; San Miguel JF; Orfao A; ;
Cancer; 2006 Mar; 106(6):1296-305. PubMed ID: 16475149
[TBL] [Abstract][Full Text] [Related]
17. Assessing the frequency of CD163+ tumor-associated macrophages and CD3+ T lymphocytes between MGUS and plasma cell myeloma.
Niblock A; Rajendran S; Laverty C; Logue P; Alexander HD
Exp Hematol; 2023; 119-120():3-7. PubMed ID: 36516929
[TBL] [Abstract][Full Text] [Related]
18. Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors.
Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Pawlak E; Frydecka I; Szmyrka M; Kosmaczewska A
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982802
[TBL] [Abstract][Full Text] [Related]
19. Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients.
Vuckovic S; Bryant CE; Lau KHA; Yang S; Favaloro J; McGuire HM; Clark G; de St Groth BF; Marsh-Wakefield F; Nassif N; Abadir E; Vanguru V; McCulloch D; Brown C; Larsen S; Dunkley S; Khoo L; Gibson J; Boyle R; Joshua D; Ho PJ
Blood Adv; 2020 Oct; 4(19):4593-4604. PubMed ID: 32986791
[TBL] [Abstract][Full Text] [Related]
20. Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?
Steiner N; Hajek R; Nachbaur D; Borjan B; Sevcikova S; Göbel G; Gunsilius E
Dis Markers; 2019; 2019():1806034. PubMed ID: 30809317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
